ALK and neuroblastoma: Lorlatinib’s known ability to overcome common resistance mutations that emerge from earlier-generation ALK TKIs, coupled with its excellent central nervous system (CNS) penetration, makes it a highly promising candidate for other ALK-driven malignancies, particularly those with a propensity for CNS metastases, such as neuroblastoma.